IVUS Use in Peripheral Vascular Disease: Should this Tool Be Used More Frequently in Peripheral Interventions?

Use of intravascular ultrasound (IVUS) has increased rapidly, and several randomized and observational studies have shown improved results in patients who underwent coronary angioplasty using this tool.

¿Es frecuente el uso de IVUS para guiar la ATC?

However, evidence on IVUS on peripheral interventions is more limited. Observational studies have found similar benefits when IVUS was part of the revascularization strategy. In a meta-analysis of eight observational studies, IVUS use had similar results in terms of patency and re-intervention compared with angiography alone but was linked to a lower rate of peri-procedural adverse events and vascular complications.

The aim of this retrospective study was to evaluate the trend, the variation, and the results of IVUS use during peripheral interventions among patients with health insurance.

The primary endpoint (PEP) was major adverse limb-related events (MALE), defined as a composite of acute lower-limb ischemia (thrombosis/embolism) or major limb amputation. The secondary endpoint (SEP) included minor amputation (defined as forefoot or finger joint amputation).

The study included a total of 543,488 patients who underwent peripheral intervention, of whom 11.7% used IVUS. There was an increase in IVUS use. Mean patient age was 76 years old, and most subjects were male. Femoropopliteal disease was the most frequent type. The most frequent clinical presentation was intermittent claudication, followed by critical lower-limb ischemia.

Read also: Changes in Decision-Making Based on OCT.

In terms of the PEP, IVUS use significantly decreased the MALE index (p < 0.0001), lower-limb acute ischemia (p < 0.0001), and major amputation (p < 0.0001). When analyzing the SEP results, minor amputation (p < 0.0001) or any amputation (p < 0.0001) rates were also lower when using IVUS.

Conclusion

According to data provided by this study, IVUS use has increased in peripheral interventions since 2016. When used as a therapeutic strategy, there has been an improvement in results—including MALE rates. Prospective studies are needed to confirm IVUS usefulness and to detect the specific clinical scenarios where it can be used in the decision-making process.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Temporal Trends, Practice Variation, and Associated Outcomes With IVUS Use During Peripheral Arterial Intervention.

Reference: Sanjay Divakaran, MD et al J Am Coll Cardiol Intv 2022;15:2080–2090.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...

ACC 2026 | SirPAD Trial: Sirolimus-coated balloon angioplasty in infrainguinal arterial disease

Paclitaxel-coated balloons have demonstrated improved patency in peripheral arterial disease (PAD), although questions remain regarding safety and applicability across different vascular territories. In this...

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...